To include your compound in the COVID-19 Resource Center, submit it here.

Trillium reports Phase I data for TTI-621 in DLBCL

Trillium Therapeutics Inc. (TSX:TRIL; NASDAQ:TRIL) reported data from 18 evaluable patients with diffuse large B cell lymphoma (DLBCL) in the dose-expansion

Read the full 215 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE